Does tafamidis help treat patients with transthyretin amyloid cardiomyopathy?

A Multicenter, International, Phase 3, Double Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)

Category & Conditions:
Cardiovasular Diseases and Conditions
Medicine:
VYNDAQEL® (TAFAMIDIS MEGLUMINE) CAPSULES AND VYNDAMAX™ (TAFAMIDIS) CAPSULES
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B3461028
Open Plain Language Summary Result:Click here